3 results
Approved WMOWill not start
The primary objective of this study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.Secondary objectives include evaluation of the safety and effect of ambrisentan on development of…
Approved WMOPending
The primary objective is to estimate the average relative change from baseline in tumoruptake of [89Zr]Zr-BI 765063 (arm A) or [89Zr]Zr-BI 770371 (arm B) upon treatment with BI 765063 (arm A) or BI 770371 (arm B).
Approved WMOPending
To investigate the maximum tolerated dose (MTD) of BI 907828 in combination with ezabenlimab based on dose limiting toxicities (DLT) during the first treatment cycle and the recommended dose for expansion (RDE), safety and tolerability,…